Evidence map›Paper›PMID 37791063›Full record

ArticleOpen life sciences2023

Ezrin promotes esophageal squamous cell carcinoma progression via the Hippo signaling pathway.

Lijuan Ma, Li Liu, Min Ji, Liping Su, Yaling Guan, Jinling Xiao, Hongwei Pu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open life sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lijuan MaState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Department of Physiology, School of Basic Medical Sciences, Xinjiang Medical University, No. 567, Shangde North Road, Urumqi 830017, Xinjiang, China.
Li LiuDepartment of Pathology, First Affiliated Hospital, Xinjiang Medical University, No. 137, Liyushan South Road, Urumqi 830054, Xinjiang, China.
Min JiDepartment of Pathology, First Affiliated Hospital, Xinjiang Medical University, No. 137, Liyushan South Road, Urumqi 830054, Xinjiang, China.
Liping SuDepartment of Pathology, First Affiliated Hospital, Xinjiang Medical University, No. 137, Liyushan South Road, Urumqi 830054, Xinjiang, China.
Yaling GuanDepartment of Pathology, School of Basic Medical Sciences, Xinjiang Medical University, No. 567, Shangde North Road, Urumqi 830017, Xinjiang, China.
Jinling XiaoDepartment of Pathology, School of Basic Medical Sciences, Xinjiang Medical University, No. 567, Shangde North Road, Urumqi 830017, Xinjiang, China.
Hongwei PuDepartment of Discipline Construction, First Affiliated Hospital, Xinjiang Medical University, No. 137, Liyushan South Road, Urumqi 830054, Xinjiang, China.
Xinjiang Medical University · CNFirst Affiliated Hospital of Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to analyze the role of Ezrin in esophageal squamous cell carcinoma (ESCC) and investigate potential therapeutic targets for ESCC by interfering with Ezrin expression. Bioinformatics analysis revealed that Ezrin expression differed significantly among patients with different clinical stage ESCC. Moreover, there was a significant correlation between Ezrin and yes-associated protein/connective tissue growth factor (YAP

Indexed as

connective tissue growth factoresophageal squamous cell carcinomaezrinHippo signaling pathwayyes-associated protein

Identifiers

PMID37791063
PMCPMC10543706
OpenAlexW4387224334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.